Portugal consome 5% de nuclear, mas centrais no país ainda são tabu

[Toni Curtes]

Depois de um longo trajeto ascendente que terminou em Outubro, a MDVN foi deslizando tendo aparentemente encontrado suporte junto à MM200. Seria um bom momento para uma entrada longa com um stop ligeiramente abaixo da referida MM. O problema é que apresenta resultados hoje após o fecho e pela parte que me toca, dou-me mal com a apresentação de resultados. De qualquer maneira deixo o gráfico

[BearManBull]

Bottom fishing

Uma pesquisa no Google...

[AC Investor Blog]

MDVN disparou hoje acima dos $100 !!! e a XNPT arrancou uns 23% de ganho.

Esta terça-feira chamei atenção para um possivel breakout neste titulo. Fica a minha análise à XNPT publicada à minutos "I had this stock on my watch list and it did not disappoint. Congrats everyone who bought XenoPort, Inc. (NASDAQ:XNPT) when I put out an alert on it this Tuesday, check http://ac-investor.blogspot.com/2012/07 ... watch.html . The stock has gained more than 35% value in the last three sessions. XenoPort shares are clearly under accumulation as traders become familiar with this company's potential. The accumulation line continues to scale new peaks as somebody out there gets extra-hungry for XNPT at these levels. The stock hit a high of $8.50, which is now resistance for Friday’s continuation move. If the stock can break through resistance, we should see another strong upside move. XNPT will move very quickly, so watch the stock closely on Friday."

[AC Investor Blog]

MDVN continua imbatível e já se aproxima dos $100. A valorização tem sido fantástica.

[AC Investor Blog]

Fica aqui a minha análise publicada à minutos. Desculpem o inglês.

"The company on the spotlight today is XenoPort, Inc., a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates, which utilizes the body’s natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. The stock on Friday surged 5% or 23 cents to $4.83 per share at two times average volume after the company announced that has received confirmation from its partner, Astellas Pharma Inc., that, following a meeting on December 2, 2011 in Japan, the drug evaluation committee of the Japanese Ministry of Health, Labor and Welfare ("MHLW") recommended approval of gabapentin enacarbil, which will be known by the trade name Regnite in Japan, for the treatment of Restless Legs Syndrome. This positive recommendation will be reviewed by the MHLW prior to its final decision on authorizing the marketing of Regnite in Japan for the treatment of Restless Legs Syndrome. The MHLW will issue a final notification to Astellas regarding its decision, which the Company expects to occur in the first quarter of 2012.

Lets take look at the stock in more detail to see if this is the stock worth buying. XNPT is trading above its 13-day moving average and is approaching its 50-day moving average. A strong bullish trend is often established once shares cross the 50-day MA. The stock has witnessed phenomenal gains in valuation when volume enters. For example, in August shares of XNPT experienced a surge of over 38% in just 5 days !! So, with an influx of volume and light resistance above, the stock could make a solid upward move. There has been building support on shares of XNPT in the past few days with overall higher highs and higher lows, and I believe that from current levels which I believe are now trading at a deep discount from the past investors could witness a solid appreciation in value. "

[AC Investor Blog]

Mantenho a posição na XNPT.

As noticias de hoje da Reuters reforçam a minha apetência pelo titulo : As instituições detêem actualmente 88% do free float.

Fica a noticia : http://www.reuters.com/article/2011/12/ ... ews&rpc=43

[Tridion]

Sendo as biotech muito voláteis e dadas a movimentos muito bruscos como é que reduzes o risco dos teus trades, colocas stops mais folgados? Arriscas menos capital? Ou simplesmente fazes um trade "à lá BCP" e se o dinheiro sumir sumiu!

Obrigado.

[AC Investor Blog]

Puxei este tópico criado por mim. Neste momento a MDVN já subiu 200% desde, mas a XNPT ainda está em banho-maria. Entrei longo abaixo dos $5 num processo chamado Bottom fishing

[Laaz Rockit]

que título enganador

[canguru]

que título enganador

[joaoparker]

A MDVN foi-se posicionar junto ao suporte dos 12,50, por isso é capaz de merecer uma entrada longa.

[AC Investor Blog]

Entrada longa na MDVN , XNPT e finalmente OSIR..... aproveitar estes preços para uma recuperação. Atênção : Estas sugestões é só para quem está habituado a negociar Biotechs.....